Benzinga | Dec 6, 2021 11:20AM EST

Guggenheim Maintains Buy on Adicet Bio, Raises Price Target to $32

Guggenheim analyst Michael Schmidt maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $22 to $32.